Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and expansion.
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: INCB000928
- drug: ruxolitinib
Eligibility
Inclusion Criteria:
- Participants with MF who are transfusion-dependent or present with symptomatic anemia,
defined as follows:
1. Anemia: An Hgb value < 10 g/dL demonstrated during screening recorded on 3
separate occasions with at least 7 days between measurements (Note: RBC
transfusion must be at least 2 weeks before the Hgb measurement during
screening).
2. Transfusion-dependent: Participant has received at least 4 units of RBC
transfusions during the 28 days immediately preceding Cycle 1 Day 1 OR has
received an average of at least 4 units of RBC transfusions in the 8 weeks
immediately preceding Cycle 1 Day 1, for an Hgb level of < 8.5 g/dL, in the
absence of bleeding or treatment-induced anemia. In addition, the most recent
transfusion episode must have occurred in the 28 days before Cycle 1 Day 1.
- ECOG performance status score of the following:
1. 0 or 1 for the dose-escalation stages.
2. 0, 1, or 2 for the dose-expansion stage.
- Life expectancy is greater than 6 months
- Agreement to avoid pregnancy or fathering children.
- Ineligible to receive or have not responded to available therapies for anemia such as
ESAs.
- For TGA:
- Participants previously treated with JAK inhibitors for at least 12 weeks.
- Participants with intermediate-2 or high DIPSS MF according to IWG-MRT criteria.
- For TGB:
- Participants must have been on a therapeutic and stable regimen of ruxolitinib for at
least 12 consecutive weeks immediately preceding the first dose of study treatment.
- Participants with intermediate-1, intermediate-2, or high DIPSS MF according to
IWG-MRT criteria.
- For TGC:
- Participants must be JAK inhibitor treatment naive (no prior treatment with any JAK
inhibitor) and have an indication for initiation of ruxolitinib treatment.
- Participants with intermediate-1, intermediate-2, or high DIPSS MF according to
IWG-MRT criteria.
Exclusion Criteria:
- Undergone any prior allogenic or autologous stem cell transplantation or a candidate
for such transplantation.
- Any prior chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy,
biological therapy, endocrine therapy, targeted therapy, antibody or hypomethylating
agent to treat the participant's disease, with the exception of ruxolitinib for TGB
only, within 5 half-lives or 28 days (whichever is shorter) before the first dose of
study treatment.
- Laboratory Values outside of protocol defined range at screening.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Justin Abuel
jabuel@stanford.edu
I'm interested
Psoriasis Clinical Trials
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and expansion.
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: INCB000928
- drug: ruxolitinib
Eligibility
Inclusion Criteria:
- Participants with MF who are transfusion-dependent or present with symptomatic anemia,
defined as follows:
1. Anemia: An Hgb value < 10 g/dL demonstrated during screening recorded on 3
separate occasions with at least 7 days between measurements (Note: RBC
transfusion must be at least 2 weeks before the Hgb measurement during
screening).
2. Transfusion-dependent: Participant has received at least 4 units of RBC
transfusions during the 28 days immediately preceding Cycle 1 Day 1 OR has
received an average of at least 4 units of RBC transfusions in the 8 weeks
immediately preceding Cycle 1 Day 1, for an Hgb level of < 8.5 g/dL, in the
absence of bleeding or treatment-induced anemia. In addition, the most recent
transfusion episode must have occurred in the 28 days before Cycle 1 Day 1.
- ECOG performance status score of the following:
1. 0 or 1 for the dose-escalation stages.
2. 0, 1, or 2 for the dose-expansion stage.
- Life expectancy is greater than 6 months
- Agreement to avoid pregnancy or fathering children.
- Ineligible to receive or have not responded to available therapies for anemia such as
ESAs.
- For TGA:
- Participants previously treated with JAK inhibitors for at least 12 weeks.
- Participants with intermediate-2 or high DIPSS MF according to IWG-MRT criteria.
- For TGB:
- Participants must have been on a therapeutic and stable regimen of ruxolitinib for at
least 12 consecutive weeks immediately preceding the first dose of study treatment.
- Participants with intermediate-1, intermediate-2, or high DIPSS MF according to
IWG-MRT criteria.
- For TGC:
- Participants must be JAK inhibitor treatment naive (no prior treatment with any JAK
inhibitor) and have an indication for initiation of ruxolitinib treatment.
- Participants with intermediate-1, intermediate-2, or high DIPSS MF according to
IWG-MRT criteria.
Exclusion Criteria:
- Undergone any prior allogenic or autologous stem cell transplantation or a candidate
for such transplantation.
- Any prior chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy,
biological therapy, endocrine therapy, targeted therapy, antibody or hypomethylating
agent to treat the participant's disease, with the exception of ruxolitinib for TGB
only, within 5 half-lives or 28 days (whichever is shorter) before the first dose of
study treatment.
- Laboratory Values outside of protocol defined range at screening.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Justin Abuel
jabuel@stanford.edu
I'm interested
Dermatology Clinical Trials
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and expansion.
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: INCB000928
- drug: ruxolitinib
Eligibility
Inclusion Criteria:
- Participants with MF who are transfusion-dependent or present with symptomatic anemia,
defined as follows:
1. Anemia: An Hgb value < 10 g/dL demonstrated during screening recorded on 3
separate occasions with at least 7 days between measurements (Note: RBC
transfusion must be at least 2 weeks before the Hgb measurement during
screening).
2. Transfusion-dependent: Participant has received at least 4 units of RBC
transfusions during the 28 days immediately preceding Cycle 1 Day 1 OR has
received an average of at least 4 units of RBC transfusions in the 8 weeks
immediately preceding Cycle 1 Day 1, for an Hgb level of < 8.5 g/dL, in the
absence of bleeding or treatment-induced anemia. In addition, the most recent
transfusion episode must have occurred in the 28 days before Cycle 1 Day 1.
- ECOG performance status score of the following:
1. 0 or 1 for the dose-escalation stages.
2. 0, 1, or 2 for the dose-expansion stage.
- Life expectancy is greater than 6 months
- Agreement to avoid pregnancy or fathering children.
- Ineligible to receive or have not responded to available therapies for anemia such as
ESAs.
- For TGA:
- Participants previously treated with JAK inhibitors for at least 12 weeks.
- Participants with intermediate-2 or high DIPSS MF according to IWG-MRT criteria.
- For TGB:
- Participants must have been on a therapeutic and stable regimen of ruxolitinib for at
least 12 consecutive weeks immediately preceding the first dose of study treatment.
- Participants with intermediate-1, intermediate-2, or high DIPSS MF according to
IWG-MRT criteria.
- For TGC:
- Participants must be JAK inhibitor treatment naive (no prior treatment with any JAK
inhibitor) and have an indication for initiation of ruxolitinib treatment.
- Participants with intermediate-1, intermediate-2, or high DIPSS MF according to
IWG-MRT criteria.
Exclusion Criteria:
- Undergone any prior allogenic or autologous stem cell transplantation or a candidate
for such transplantation.
- Any prior chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy,
biological therapy, endocrine therapy, targeted therapy, antibody or hypomethylating
agent to treat the participant's disease, with the exception of ruxolitinib for TGB
only, within 5 half-lives or 28 days (whichever is shorter) before the first dose of
study treatment.
- Laboratory Values outside of protocol defined range at screening.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Justin Abuel
jabuel@stanford.edu
I'm interested
Pediatric Dermatology Clinical Trials
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and expansion.
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: INCB000928
- drug: ruxolitinib
Eligibility
Inclusion Criteria:
- Participants with MF who are transfusion-dependent or present with symptomatic anemia,
defined as follows:
1. Anemia: An Hgb value < 10 g/dL demonstrated during screening recorded on 3
separate occasions with at least 7 days between measurements (Note: RBC
transfusion must be at least 2 weeks before the Hgb measurement during
screening).
2. Transfusion-dependent: Participant has received at least 4 units of RBC
transfusions during the 28 days immediately preceding Cycle 1 Day 1 OR has
received an average of at least 4 units of RBC transfusions in the 8 weeks
immediately preceding Cycle 1 Day 1, for an Hgb level of < 8.5 g/dL, in the
absence of bleeding or treatment-induced anemia. In addition, the most recent
transfusion episode must have occurred in the 28 days before Cycle 1 Day 1.
- ECOG performance status score of the following:
1. 0 or 1 for the dose-escalation stages.
2. 0, 1, or 2 for the dose-expansion stage.
- Life expectancy is greater than 6 months
- Agreement to avoid pregnancy or fathering children.
- Ineligible to receive or have not responded to available therapies for anemia such as
ESAs.
- For TGA:
- Participants previously treated with JAK inhibitors for at least 12 weeks.
- Participants with intermediate-2 or high DIPSS MF according to IWG-MRT criteria.
- For TGB:
- Participants must have been on a therapeutic and stable regimen of ruxolitinib for at
least 12 consecutive weeks immediately preceding the first dose of study treatment.
- Participants with intermediate-1, intermediate-2, or high DIPSS MF according to
IWG-MRT criteria.
- For TGC:
- Participants must be JAK inhibitor treatment naive (no prior treatment with any JAK
inhibitor) and have an indication for initiation of ruxolitinib treatment.
- Participants with intermediate-1, intermediate-2, or high DIPSS MF according to
IWG-MRT criteria.
Exclusion Criteria:
- Undergone any prior allogenic or autologous stem cell transplantation or a candidate
for such transplantation.
- Any prior chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy,
biological therapy, endocrine therapy, targeted therapy, antibody or hypomethylating
agent to treat the participant's disease, with the exception of ruxolitinib for TGB
only, within 5 half-lives or 28 days (whichever is shorter) before the first dose of
study treatment.
- Laboratory Values outside of protocol defined range at screening.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Justin Abuel
jabuel@stanford.edu
I'm interested
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and expansion.
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: INCB000928
- drug: ruxolitinib
Eligibility
Inclusion Criteria:
- Participants with MF who are transfusion-dependent or present with symptomatic anemia,
defined as follows:
1. Anemia: An Hgb value < 10 g/dL demonstrated during screening recorded on 3
separate occasions with at least 7 days between measurements (Note: RBC
transfusion must be at least 2 weeks before the Hgb measurement during
screening).
2. Transfusion-dependent: Participant has received at least 4 units of RBC
transfusions during the 28 days immediately preceding Cycle 1 Day 1 OR has
received an average of at least 4 units of RBC transfusions in the 8 weeks
immediately preceding Cycle 1 Day 1, for an Hgb level of < 8.5 g/dL, in the
absence of bleeding or treatment-induced anemia. In addition, the most recent
transfusion episode must have occurred in the 28 days before Cycle 1 Day 1.
- ECOG performance status score of the following:
1. 0 or 1 for the dose-escalation stages.
2. 0, 1, or 2 for the dose-expansion stage.
- Life expectancy is greater than 6 months
- Agreement to avoid pregnancy or fathering children.
- Ineligible to receive or have not responded to available therapies for anemia such as
ESAs.
- For TGA:
- Participants previously treated with JAK inhibitors for at least 12 weeks.
- Participants with intermediate-2 or high DIPSS MF according to IWG-MRT criteria.
- For TGB:
- Participants must have been on a therapeutic and stable regimen of ruxolitinib for at
least 12 consecutive weeks immediately preceding the first dose of study treatment.
- Participants with intermediate-1, intermediate-2, or high DIPSS MF according to
IWG-MRT criteria.
- For TGC:
- Participants must be JAK inhibitor treatment naive (no prior treatment with any JAK
inhibitor) and have an indication for initiation of ruxolitinib treatment.
- Participants with intermediate-1, intermediate-2, or high DIPSS MF according to
IWG-MRT criteria.
Exclusion Criteria:
- Undergone any prior allogenic or autologous stem cell transplantation or a candidate
for such transplantation.
- Any prior chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy,
biological therapy, endocrine therapy, targeted therapy, antibody or hypomethylating
agent to treat the participant's disease, with the exception of ruxolitinib for TGB
only, within 5 half-lives or 28 days (whichever is shorter) before the first dose of
study treatment.
- Laboratory Values outside of protocol defined range at screening.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Justin Abuel
jabuel@stanford.edu
I'm interested
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and expansion.
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: INCB000928
- drug: ruxolitinib
Eligibility
Inclusion Criteria:
- Participants with MF who are transfusion-dependent or present with symptomatic anemia,
defined as follows:
1. Anemia: An Hgb value < 10 g/dL demonstrated during screening recorded on 3
separate occasions with at least 7 days between measurements (Note: RBC
transfusion must be at least 2 weeks before the Hgb measurement during
screening).
2. Transfusion-dependent: Participant has received at least 4 units of RBC
transfusions during the 28 days immediately preceding Cycle 1 Day 1 OR has
received an average of at least 4 units of RBC transfusions in the 8 weeks
immediately preceding Cycle 1 Day 1, for an Hgb level of < 8.5 g/dL, in the
absence of bleeding or treatment-induced anemia. In addition, the most recent
transfusion episode must have occurred in the 28 days before Cycle 1 Day 1.
- ECOG performance status score of the following:
1. 0 or 1 for the dose-escalation stages.
2. 0, 1, or 2 for the dose-expansion stage.
- Life expectancy is greater than 6 months
- Agreement to avoid pregnancy or fathering children.
- Ineligible to receive or have not responded to available therapies for anemia such as
ESAs.
- For TGA:
- Participants previously treated with JAK inhibitors for at least 12 weeks.
- Participants with intermediate-2 or high DIPSS MF according to IWG-MRT criteria.
- For TGB:
- Participants must have been on a therapeutic and stable regimen of ruxolitinib for at
least 12 consecutive weeks immediately preceding the first dose of study treatment.
- Participants with intermediate-1, intermediate-2, or high DIPSS MF according to
IWG-MRT criteria.
- For TGC:
- Participants must be JAK inhibitor treatment naive (no prior treatment with any JAK
inhibitor) and have an indication for initiation of ruxolitinib treatment.
- Participants with intermediate-1, intermediate-2, or high DIPSS MF according to
IWG-MRT criteria.
Exclusion Criteria:
- Undergone any prior allogenic or autologous stem cell transplantation or a candidate
for such transplantation.
- Any prior chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy,
biological therapy, endocrine therapy, targeted therapy, antibody or hypomethylating
agent to treat the participant's disease, with the exception of ruxolitinib for TGB
only, within 5 half-lives or 28 days (whichever is shorter) before the first dose of
study treatment.
- Laboratory Values outside of protocol defined range at screening.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Justin Abuel
jabuel@stanford.edu
I'm interested